Corgentech drug found to reduce inflammation in bowel disease
“California-based biotechnology firm Corgentech has received positive preclinical data from studies investigating its NF-kappaB Decoy drug candidate. The results show the drug to be effective at reducing disease activity in acute inflammatory bowel disease.
“The studies used rodent models of chronic Crohn’s disease and ulcerative colitis, `both also referred inflammatory bowel disease (IBD). The kappaB Decoy was shown to be efficiently delivered to inflamed areas of the gut, significantly reduced inflammatory cell infiltrates and expression of proinflammatory genes, and reversed disease associated weight loss and tissue damage in multiple chronic and acute preclinical models of IBD.”
Read more at Corgentech drug found to reduce inflammation in bowel disease
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax